Hepatitis B Vaccination is Required for Dialysis Patients
All hemodialysis patients should receive hepatitis B vaccination unless they have documented immunity or current infection. 1
Vaccination Regimen for Dialysis Patients
Dialysis patients require higher doses than the general population due to impaired immune response 2, 1:
Recommended Vaccine Options:
- Recombivax HB: 40 μg (1 mL) at 0,1, and 6 months 2
- Engerix-B: 40 μg (2 mL total, given as single 2-mL dose or two 1-mL doses) at 0,1,2, and 6 months 2
Important Caveat:
Heplisav-B and PreHevbrio have NOT been established as safe or effective in hemodialysis patients and should be avoided 2. Use only Recombivax HB or Engerix-B for this population.
Pre-Vaccination Testing
All dialysis patients should undergo serologic testing before vaccination 1:
- HBsAg (hepatitis B surface antigen) - identifies current infection
- Anti-HBs (antibody to HBsAg) - indicates immunity from vaccination or prior infection
- Anti-HBc (antibody to hepatitis B core antigen) - indicates previous or ongoing infection 1
Testing should not delay vaccination - the first vaccine dose should be administered immediately after blood collection for serologic testing 1.
Post-Vaccination Monitoring
Initial Response Assessment:
- Test anti-HBs levels 1-2 months after completing the vaccine series 1, 3
- If anti-HBs <10 mIU/mL: Administer a second complete vaccine series 1
- If still non-responsive after second series: No additional doses have proven beneficial 3
Ongoing Surveillance:
Annual anti-HBs testing is mandatory for hemodialysis patients 1. This distinguishes dialysis patients from other populations and reflects their:
- Impaired immune response
- Ongoing high-risk exposure in dialysis units
- Tendency for antibody levels to decline over time
Administer booster doses when anti-HBs levels decline to <10 mIU/mL 1. Post-booster antibody testing is not recommended 1.
Clinical Rationale
The emphasis on hepatitis B vaccination in dialysis stems from:
- High historical infection rates in dialysis units before widespread vaccination 4
- 70% reduction in HBV infection risk with vaccination in this population 4
- Impaired cellular immunity in kidney failure patients, leading to reduced vaccine response (only 58% develop protective antibodies even with high-dose regimens) 3, 5
- Ongoing exposure risk from blood contact in the dialysis environment 1, 3
Common Pitfalls to Avoid
- Do not use standard adult doses (10-20 μg) - dialysis patients require 40 μg formulations 2
- Do not use Heplisav-B or PreHevbrio in dialysis patients - safety and efficacy are unestablished 2
- Do not skip annual monitoring - this is unique to dialysis patients and critical for maintaining protection 1
- Vaccinate early - patients respond better when vaccinated before dialysis initiation, but vaccination should proceed regardless of dialysis status 3